Patents by Inventor Liselotte Brix

Liselotte Brix has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12258373
    Abstract: Disclosed herein is a panel comprising one or more MHC multimers; and a panel comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers; wherein said MHC multimers comprise an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; as well as uses thereof in the detection of Borrelia-specific T cells and the diagnosis, treatment and monitoring of Borrelia disease in an individual.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: March 25, 2025
    Assignee: Immudex ApS
    Inventors: Liselotte Brix, Kivin Jacobsen, Amir Ameri
  • Publication number: 20240366738
    Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.
    Type: Application
    Filed: April 23, 2024
    Publication date: November 7, 2024
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 11992518
    Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: May 28, 2024
    Assignee: Agilent Technologies, Inc.
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Publication number: 20240150431
    Abstract: The present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples including diagnostic and prognostic methods. Furthermore, the use of MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells.
    Type: Application
    Filed: November 21, 2023
    Publication date: May 9, 2024
    Inventors: Liselotte BRIX, Henrik PEDERSEN, Tina JAKOBSEN, Jørgen SCHØLLER, Jesper LOHSE, Katja BRUNSTEDT, Kivin JACOBSEN
  • Publication number: 20220064226
    Abstract: Disclosed herein is a panel comprising one or more MHC multimers; and a panel comprising one or more pools of MHC multimers, wherein each pool comprises one or more MHC multimers; wherein said MHC multimers comprise an antigenic peptide P derived from a Borrelia antigenic polypeptide selected from the group consisting of OppA, DbpA, FlhF, FlaB and P37-42; as well as uses thereof in the detection of Borrelia-specific T cells and the diagnosis, treatment and monitoring of Borrelia disease in an individual.
    Type: Application
    Filed: December 17, 2019
    Publication date: March 3, 2022
    Inventors: Liselotte BRIX, Kivin JACOBSEN, Amir AMERI
  • Patent number: 10968269
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.
    Type: Grant
    Filed: December 30, 2008
    Date of Patent: April 6, 2021
    Assignee: Agilent Technologies, Inc.
    Inventors: Jørgen Schøller, Liselotte Brix, Henrik Pedersen
  • Publication number: 20210047383
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules containing one or more Borrelia derived peptides are disclosed. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the sample-mounted use of MHC complexes and MHC multimers. Also comprised by the invention is the field of therapy and vaccine, including therapeutic/vaccine methods and therapeutic/vaccine compositions.
    Type: Application
    Filed: June 23, 2020
    Publication date: February 18, 2021
    Inventors: Jørgen SCHØLLER, Liselotte BRIX, Henrik PEDERSEN
  • Publication number: 20200347103
    Abstract: The present invention relates to MHC peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising Mycobacterium tuberculosis antigenic peptides and uses thereof.
    Type: Application
    Filed: February 13, 2020
    Publication date: November 5, 2020
    Inventors: Jørgen SCHØLLER, Liselotte BRIX, Henrik PEDERSEN, Tina JAKOBSEN
  • Publication number: 20200347114
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.
    Type: Application
    Filed: June 13, 2019
    Publication date: November 5, 2020
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 10722562
    Abstract: A method for the repair of a unit, by specific diagnosis of the undesired state, and its appropriate repair, using said specific diagnosis as a means to repair in an appropriate way said unit. The diagnosis and repair processes may involve chemical, physical, or mechanical means. The units being diagnosed and repaired include live matter (e.g. human beings, animals, plants) as well as non-live matter (e.g. buildings, electronic equipment, polymer materials).
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: July 28, 2020
    Assignees: Immudex ApS, Agilent Technologies, Inc.
    Inventors: Henrik Pedersen, Liselotte Brix
  • Patent number: 10611818
    Abstract: The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising Mycobacterium tuberculosis antigenic peptides and uses there of.
    Type: Grant
    Filed: September 29, 2008
    Date of Patent: April 7, 2020
    Assignee: Agilent Technologies, Inc.
    Inventors: Jørgen Schøller, Liselotte Brix, Henrik Pedersen, Tina Jakobsen
  • Publication number: 20190314471
    Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.
    Type: Application
    Filed: June 27, 2019
    Publication date: October 17, 2019
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 10369204
    Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: August 6, 2019
    Assignee: Dako Denmark A/S
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 10336808
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: July 2, 2019
    Assignee: Dako Denmark A/S
    Inventors: Jøgen Schøller, Henrik Pedersen, Liselotte Brix
  • Publication number: 20190085048
    Abstract: The present invention describes novel methods to generate MHC multimers and methods to improve existing and new MHC multimers. The invention also describes improved methods for the use of MHC multimers in analysis of T-cells in samples including diagnostic and prognostic methods. Furthermore, the use of MHC multimers in therapy are described, e.g. anti-tumour and anti-virus therapy, including isolation of antigen specific T-cells capable of inactivation or elimination of undesirable targeT-cells or isolation of specific T-cells capable of regulation of other immune cells.
    Type: Application
    Filed: June 22, 2018
    Publication date: March 21, 2019
    Inventors: Liselotte Brix, Henrik Pedersen, Tina Jakobsen, Jørgen Schøller, Jesper Lohse, Katja Brunstedt, Kivin Jacobsen
  • Patent number: 10030065
    Abstract: The present invention relates to a soluble negative control MHC multimer comprising a nonsense peptide that binds the MHC protein efficiently, but that does not support binding of the resultant MHC-peptide complex to the desired T Cell Receptor. The nonsense peptide is designed to i) have a length enabling binding to the MHC allele in question, ii) have appropriate amino acids at relevant anchor positions which anchor the nonsense peptide to the peptide-binding groove of the MHC, iii) have amino acids outside the anchor positions that do not support binding to a T Cell Receptor, and iv) have an amino acid sequence that is different from the linear sequence of any naturally occurring peptide.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: July 24, 2018
    Assignee: Dako Denmark A/S
    Inventors: Liselotte Brix, Henrik Pedersen, Tina Jakobsen, Jørgen Schøller, Jesper Lohse, Katja Brunstedt, Kivin Jacobsen
  • Publication number: 20120264161
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.
    Type: Application
    Filed: May 29, 2012
    Publication date: October 18, 2012
    Applicant: DAKO DENMARK A/S
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Publication number: 20120258126
    Abstract: The present invention relates to methods for construction of pharmamers i.e. vaccine components characterized by their multimerization domain and the attached biologically active molecules, and their use in preparation of vaccines that contains the pharmamers alone or in combination with other molecules. The individual molecules of the construct can be bound to each other or the multimerization domain(s) by covalent or non-covalent bonds, directly or via linkers. The invention further relates to the use of such preparations in vaccine settings aimed to function as preventive/prophylactic or therapeutic vaccines in humans and animals.
    Type: Application
    Filed: October 2, 2009
    Publication date: October 11, 2012
    Applicant: DAKO DENMARK A/S
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Patent number: 8268964
    Abstract: Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.
    Type: Grant
    Filed: November 16, 2009
    Date of Patent: September 18, 2012
    Assignee: Dako Denmark A/S
    Inventors: Jørgen Schøller, Henrik Pedersen, Liselotte Brix
  • Publication number: 20110318380
    Abstract: The present invention relates to MHC-peptide complexes and uses thereof in the diagnosis of, treatment of or vaccination against a disease in an individual. More specifically the invention discloses MHC complexes comprising cancer antigenic peptides and uses there of.
    Type: Application
    Filed: October 1, 2009
    Publication date: December 29, 2011
    Applicant: DAKO DENMARK A/S
    Inventors: Liselotte Brix, Jørgen Schøller, Henrik Pedersen